[HTML][HTML] Antibody response following the intranasal administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide vaccine
K Muranishi, M Kinoshita, K Inoue, J Ohara, T Mihara… - Vaccines, 2023 - mdpi.com
The new coronavirus infection causes severe respiratory failure following respiratory tract
infection with severe acute respiratory syndrome-related coronavirus (SARS-CoV-2). All …
infection with severe acute respiratory syndrome-related coronavirus (SARS-CoV-2). All …
[HTML][HTML] Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults …
S Thomas, J Pak, S Doss-Gollin, K Ryff… - Journal of Molecular …, 2024 - Elsevier
Adjuvants are vaccine components that can boost the type, magnitude, breadth, and
durability of an immune response. We have previously demonstrated that certain adjuvant …
durability of an immune response. We have previously demonstrated that certain adjuvant …
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein
K Waki, H Tani, Y Saga, T Shimada, E Yamazaki… - bioRxiv, 2023 - biorxiv.org
Intranasal vaccination is an attractive strategy for preventing COVID-19 disease as it
stimulates the production of multimeric secretory immunoglobulin A (IgAs), the predominant …
stimulates the production of multimeric secretory immunoglobulin A (IgAs), the predominant …